Delius Pharma registers 35% growth in sales, plans IPO in next 3 years

Delius Pharma registered a 35 percent rise in sales in FY23 to 24, with plans to set up multiple manufacturing units in India for finished formulation and API production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CTbszZO
via IFTTT

0 comments:

Post a Comment